6/28/23, 12:05 AM CATCO Pathway Feedback Search Clinical Topics Home Studies CATCO CATCO Disease COVID 19 infection Trial question What is the role of remdesivir in patients with COVID-19 infection across Canada? Study design Multi-center Open label RCT Population Characteristics of study participants 40.0% female N = 1281 60.0% male 1281 patients (515 female, 766 male) Inclusion criteria: hospitalized adults with laboratory-confirmed COVID-19 infection Key exclusion criteria: allergy to study drug; anticipated transfer to a nonstudy site; expected to not survive beyond 24 hours; already receiving remdesivir at time of enrolment Interventions N=634 remdesivir (IV dose of 200 mg on day 0, followed by 100 mg daily for 10 days plus standard care) N=648 standard care (standard care alone) Primary outcome Death at day 28 22.6 % 22.6 18.7 17.0 % https://web.pathway.md/studies/rec1c9XBbrIBqnkRV 1/2 6/28/23, 12:05 AM CATCO Pathway 11.3 % 5.7 % No significant difference 0.0 % Remdesivir Standard care No significant difference in death at day 28 (18.7% vs. 22.6%; RR 0.83, 95% CI 0.67 to 1.03) Secondary outcomes Borderline significant decrease in need for mechanical ventilation (8% vs. 15%; RR 0.53, 95% CI 0.38 to 0.75) No significant difference in death at day 60 (24.8% vs. 28.2%; RR 0.88, 95% CI 0.72 to 1.07) Significant increase in oxygen-free days at day 28 (15.9 days vs. 14.2 days; AD 1.7 days, 95% CI 0.4 to 3) Safety outcomes No significant differences in need for dialysis, creatinine levels, new hepatic dysfunction. Conclusion In hospitalized adults with laboratory-confirmed COVID-19 infection, remdesivir was not superior to standard care with respect to death at day 28. Reference Karim Ali, Tanweer Azher, Mahin Baqi et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022 Feb 22;194(7):E242-E251. Open reference URL https://web.pathway.md/studies/rec1c9XBbrIBqnkRV 2/2